Clinical-stage biotech Q32 Bio prices 6.03M shares to fund development, marking a significant equity raise in the sector.
Q32 Bio Inc. (QTTB) has priced a public offering of 6.03 million shares of common stock at $18.25 per share, raising approximately $200 million in gross proceeds. The company also offered pre-funded warrants to certain investors in lieu of common stock.
The offering follows a period of heightened activity in biotech fundraising, with clinical-stage firms seeking capital to advance pipeline programs. Q32 Bio, focused on immune-mediated diseases, aims to use the proceeds for research and development.
No immediate market reaction was disclosed, but the raise underscores investor appetite for early-stage biotech opportunities.